NYSE MKT LLC · NRXS
-6.18% · -$0.4700 · Vol 110.8K
After hours · updated 18:30:00 ET
Neuraxis Inc

Neuraxis Inc

Health Care
$7.14
Card
Relationship Map

Follow $NRXS

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $NRXS by email

Veridion Score

BETAMEDIUM CONF · 6 of 6 factors measuredMethodology
NRXS
Neuraxis Inc
Mon Sep 21 · session closed · Markets closed · resumes Tue 9:30 ET
Middle range

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

59/ 100
Veridion Score
Middle range · MEDIUM confidence · 6 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: MEDIUM · 6 of 6 factors measured · Mon Sep 21 · session closed · Markets closed · resumes Tue 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is NRXS moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading NRXS catalysts
About Neuraxis Inc
ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS
Listed since
2023
Employees
24
Country
US

Neuraxis Inc is a growth-stage medical technology company focused on neuromodulation therapies for chronic and debilitating conditions in the gastrointestinal (GI) digestive system, specifically from disorders of the gut-brain interaction (DGBIs) in pediatrics and adults. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$7.69
Day high
$7.69
Day low
$7.11
Previous close
$7.61
52W high
$8.81
-18.96% from high
52W low
$2.31
74% of range
Market cap
$95.6M
EPS
$-0.8300
Beta
1.44
Shares out
12.6M
Volume
110.8K
0.82× rel vol
Avg volume
135.6K
VWAP
$7.32
Price history computed in-house
1W
+24.17%
1M
+16.10%
3M
+2.00%
1Y
+181.10%
YTD
+57.27%
SMA 50 $6.45 · above
SMA 200 $6.14 · above
52W position 74%

NRXS overview

Veridion Score
59
Registered · 2026-09-21
6 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around NRXS.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading NRXS Form 4 filings
Public disclosures

Congress activity in NRXS

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for NRXS in the cached public ledger.

Federal contracts

NRXS contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for NRXS in this window.
Lobbying spend

NRXS lobbying filings, year to date.

Registered lobbying filings matched to Neuraxis Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for NRXS in this window.
Loading news for NRXS
Analyst ratings
Sovereign unlock shows live analyst consensus for NRXS.
Options
Sovereign unlock shows live options positioning for NRXS.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.